Nivolumab plus ipilimumab for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs, nivolumab and ipilimumab, as a first treatment for liver cancer that cannot be removed by surgery or has come back after local treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have liver cancer that cannot be removed by surgery or has gotten worse after other local treatments.
- Your liver function is good (Child-Pugh class A).
- You have not had any previous drug treatment for your liver cancer, except certain cases like lenvatinib with TACE.
- You are ready to start the study treatment between March 2026 and February 2027.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of treatments for liver cancer that cannot be removed by surgery. It uses a special radiation therapy called Y90 along with other drugs to see if they work better together.
This early-phase study tests how well giving ipilimumab directly into the liver (via an artery) and nivolumab through a vein works for advanced hepatocellular carcinoma (liver cancer). It is for people whose cancer cannot be removed with surgery or treated with a transplant, especially after standard treatment failed or wasn’t tolerated.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.